MD3 CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS RECEIVING INFLIXIMAB—RESULTS FROM ANALYSIS OFTHE BRITISH SOCETY FOR RHEUMATOLOGY'S BIOLOGICS REGISTER (BSRBR)  by Gibbons, CJ et al.
selective B cell therapy) + methotrexate [MTX] as an alternative
for the treatment of patients with an inadequate response to
anti-tumour necrosis factor [TNF] therapies in rheumatoid
arthritis [RA] in The Netherlands [NL]. This analysis was per-
formed as part of a reimbursement request. Currently RTX is
reimbursed according to the Dutch Expensive Hospital Drug Act.
METHODS: A cost-effectiveness model was developed to evalu-
ate the societal costs and clinical outcomes of a standard Dutch
treatment sequence either with or without RTX + MTX. The
model uses Monte Carlo simulation to generate 10,000 random
RA patients who start with 2nd line treatment after an inad-
equate response to TNF therapy + MTX. Baseline patient char-
acteristics were taken from the RTX registration study, REFLEX.
Efﬁcacy data were taken from published literature and were
placebo-adjusted to minimise bias from cross-trial comparisons.
Dutch observational data were collected in order to determine
local treatment patterns and resource utilisation data. Both direct
and indirect medical costs were based on ofﬁcial price lists
(2005). Costs and beneﬁts were discounted at 4% and 1.5%,
respectively. RESULTS: The average lifetime treatment costs per
patient in NL were €131,531 for the current treatment sequence
and €141,544 when RTX + MTX was added. QALYs gained
were 3.76 for the current treatment sequence and 4.4 when
RTX + MTX was added. The incremental cost-effectiveness ratio
for inclusion of RTX + MTX in the current treatment sequence
was €13,903/QALY. CONCLUSION: Adding RTX + MTX to
the current treatment sequence is predicted to increase QALYs
with a slight increase in overall lifetime costs for the society.
These favourable outcomes are driven by the lower annual drug
therapy costs compared with other biological alternatives.
MD3
CHANGES IN BODYWEIGHT AND ASSOCIATED DOSING
REQUIREMENTS FOR RHEUMATOID ARTHRITIS PATIENTS
RECEIVING INFLIXIMAB—RESULTS FROM ANALYSIS OFTHE
BRITISH SOCETY FOR RHEUMATOLOGY’S BIOLOGICS
REGISTER (BSRBR)
Gibbons CJ, Morris J,Abhyankar B
Schering-Plough,Welwyn Garden City, UK
OBJECTIVES: To proﬁle the weight change observed in rheuma-
toid arthritis (RA) patients receiving inﬂiximab, in order to
understand the expected change in their dosing requirements
over time on treatment. METHODS: A total 3211 RA patients
(2436 males [24%], 775 females [76%]) with valid bodyweight
and follow-up measurements from the BSRBR were analysed.
Weight change was initially modelled by follow-up (FUP)
number using ordinary least-squares linear regression adjusted
for sex and patient’s total number of visits. Standard errors were
adjusted for clustering on study ID. RESULTS: The main analysis
modelled FUP as a categorical variable. This analysis showed
that the change in average bodyweight did not follow a steady
slope, but rather was characterized by a rapid, statistically sig-
niﬁcant increase of about 1 kg on the ﬁrst visit after baseline
followed by a slow, uneven and statistically nonsigniﬁcant
upward trend over subsequent follow-up visits. This modelling
technique gave a signiﬁcantly better ﬁt (p = 0.006) over that
possible if treating follow-up number as a continuous variable.
To test for possible biases attributable to drop-out, the analysis
was repeated in several subsets of patients who had all completed
the same number of follow-up visits. Despite statistically nonsig-
niﬁcant or statistically borderline estimates in these subsets, the
ﬁndings were similar to those reported in the main results. CON-
CLUSION: Translating observed bodyweight into an expected
number of vials required at each visit using basic 3 mg/kg dosing
shows that the observed weight gain in the BSRBR’s inﬂiximab
patients does not correspond to a statistically signiﬁcant change
in the total number of vials of inﬂiximab required. Although the
dosing in real-life clinical practice tends to vary, the results of this
analysis demonstrate that the weight gain observed during inﬂix-
imab treatment of RA patients is unlikely to have an indepen-
dent, critical impact on the resource implications for these
patients as their treatment continues.
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OBJECTIVES: To evaluate the cost-effectiveness of bone densi-
tometry screening for Belgian women aged 55 and older com-
bined with 5 years Alendronate therapy in osteoporotic women
(femoral neck t-score -2.5) versus no screening and no treat-
ment. METHODS: A microsimulation Markov model was devel-
oped. The model used a lifetime horizon, a Belgian societal
perspective and recorded the full patient history by the use of
tracker variables. Each prior fracture had an impact on transition
probabilities, costs and QALY level. All the model parameters
were selected from Belgian literature when available and from
systematic literature review otherwise. Analyses were realized at
the ages of 55, 60, 65, 70, 75, 80 and 85 years and for women
with 0 to 4 clinical risk factors. Sensitivity analyses were run on
persistence level. RESULTS: Costs per QALY gained for the
screen and treat strategy versus no intervention with optimal
persistence and no clinical risk factor were €49,711, €25,392 and
€10,487 for the ages of 55, 65 and 75 years respectively. With
realistic persistence, these values were respectively €61,373,
€35,780 and €14,302. With one clinical risk factor and optimal
persistence, these values were €31,320, €11,507 and cost-saving.
And with two clinical risk factors, these values were €18,206,
€2,588 and cost-saving. CONCLUSION: Universal bone densi-
tometry followed by Alendronate treatment in the presence of
osteoporosis seems highly cost-effective (cost per QALY gained
€30,000) for women aged 65 and older (with optimal persis-
tence), for women aged 70 and older (with realistic persistence)
and for women with at least one clinical risk factor aged 60 or
older (even under realistic persistence assumption). We con-
cluded that screening individuals with or more clinical risk
factors is more cost-effective than universal screening and should
be recommended.
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OBJECTIVES: To estimate, from the hospital perspective, the
cost effectiveness of FOND versus ENOX for prevention and
treatment of VTE in MOSLL patients in Germany (42% with
total hip replacement, 33% with total knee replacement, 25%
with hip-fracture surgery). METHODS: The incremental cost-
effectiveness ratio ‘additional cost for FOND per clinical VTE
A236 Abstracts
